FDA sunscreen approval rules loosened; safety standards shift to faster track
H.R. 3686 — SAFE Sunscreen Standards Act · Filed by John Joyce (R-PA) · 9 cosponsors · Introduced Jun 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal law to streamline FDA approval of new sunscreen active ingredients by allowing the use of real-world evidence, observational studies, and non-animal testing methods alongside traditional clinical trials. It aims to accelerate the introduction of new sunscreen products to the U.S. market, which has seen no new active ingredients approved since 1999, despite rising skin cancer rates and the 2014 Sunscreen Innovation Act's stated intent to speed approvals.
Why we flagged it
The bill's core mechanism is deregulatory—it loosens FDA approval standards for sunscreen ingredients by permitting alternative evidence types (real-world data, observational studies, non-animal testing) to replace or supplement traditional clinical trials. This is framed as public health acceleration but operationally reduces the evidentiary bar.
What the text implies
- Real-world evidence and observational studies are inherently weaker than randomized controlled trials for establishing causation and safety; substituting them for clinical trials may allow ingredients with undetected adverse effects to reach consumers.
- Non-animal testing methods (in vitro, computational models) are faster and cheaper but have not been validated as equivalent to animal and human safety data for topical absorption and systemic toxicity in sunscreen actives.
The full analysis lists 5 implications of this text.
Who stands to gain
sunscreen manufacturers and cosmetic companies; contract research organizations (CROs) specializing in real-world evidence and non-animal testing; ingredient suppliers seeking faster market entry